Skip to main content
Premium Trial:

Request an Annual Quote

Celera s Revenues Down, Losses Narrowed in Q4; Firm Will Sell Rockville Facility

This article has been updated from a previous version. Click here for the original article.

NEW YORK, July 28 (GenomeWeb News) - Celera Genomics today reported narrowed losses and a drop in revenues in the fourth quarter of its fiscal year 2004.

It also said that it was planning to sell its facility in Rockville, Md.

 

Celera, a unit of Applera, reported a net loss of $5.8 million for Q4 2004 as compared to $19.4 million in Q4 2003. The company said the Q4 results included a $24.8 million pre-tax gain associated with the sale of its investment in Discovery Partners International, as well as an $18.1 million non-cash pre-tax charge representing the estimated loss on the planned Rockvillesale.

 

The $18.1 million write-off is due to losses Celera expects to incur after selling the two-building facility in Rockville. Robert Bennett, a spokesman for the company, said Celera bought the property at the height of the market and would sell it at a loss.

 

He also said the company would lease the facility from its new owners, and retain the proteomics and bioinformatics divisions that work there.

 

Celera's revenues decreased to $12.4 million in Q4 2004, from $21.5 million in the same quarter last year. The company attributed the losses primarily to continuing expiration of online and information business customer agreements.

 

The company saw a slight rise in its R&D spending in Q4 2004, to $29.4 million, from $28.5 million in Q4 2003. Celera said the rise was primarily to support preclinical development activities and the hiring of additional therapeutic R&D personnel.

 

As of June 30, Celera's cash and short-term investments totaled approximately $746 million.

Julia Karow contributed to this report.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.